Synchron Raises $40M to Trial Neurotech that Helps Paralysis Patients Text, Email and Shop Online.

The article deals with a clinical trial to be conducted by New York City-based Synchron to test its Stentode implant technology developed to restore communication for people with severe paralysis. Topics include the amount raised by the company from a series B funding round to start the trial, the implication of a possible U.S. Food and Drug Administration (FDA) approval of Stentode for both medicine and technology and the components of this brain-computer interface device and how it will work.